STOCK TITAN
  1. Home
  2. News
  3. DYN

Dyne Therapeutics Inc - DYN STOCK NEWS

Welcome to our dedicated news page for Dyne Therapeutics (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dyne Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dyne Therapeutics's position in the market.

News
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) has commenced an underwritten public offering of $175,000,000 of shares of its common stock, with the intention to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.28%
Tags
offering
-
News
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) announced positive initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.09%
Tags
clinical trial
-
News
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m. ET. The company will issue a press release prior to the event. The event will feature presentations and Q&A with leading neuromuscular disease experts. The live webcast will be available on Dyne's website and a replay will be accessible for 90 days. To register for the webcast and replay, visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.09%
Tags
conferences clinical trial
News
Dyne Therapeutics to Present at November Investor Conferences
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) will be presenting at two investor conferences in November, providing live webcasts and replays for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.58%
Tags
conferences
-
News
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
Rhea-AI Summary
Dyne Therapeutics reports financial results for Q3 2023 and provides an update on its ACHIEVE and DELIVER clinical trials. Over 72 patients enrolled and over 300 doses administered. Initial data to be presented at the J.P. Morgan Healthcare Conference in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.57%
Tags
earnings
-
News
Dyne Therapeutics to Present at October Investor Conferences
Rhea-AI Summary
Dyne Therapeutics to present at investor conferences in October
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
News
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Rhea-AI Summary
Dyne Therapeutics receives FDA orphan drug designation for DYNE-101, potential transformative therapy for myotonic dystrophy type 1 (DM1). Initial data from ACHIEVE trial expected in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
clinical trial
-
News
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Summary
Dyne Therapeutics to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
-
News
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
News
Dyne Therapeutics to Present at Jefferies Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
conferences
Stock DYN logo
Dyne Therapeutics Inc

Nasdaq:DYN

DYN Rankings

#2162 Ranked by Market Cap
#4413 Ranked by Stock Gains
N/A Ranked by Dividends

DYN Stock Data

2.23B
52.67M
0.91%
86.03%
9.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About DYN

dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.